Ralph Herbst
About Ralph Herbst
Ralph Herbst serves as the Chief Strategy Officer at Asklepios BioPharmaceutical, Inc. He has extensive experience in strategy and business planning within the pharmaceutical industry, particularly in cell and gene therapy.
Work at Asklepios BioPharmaceutical
Ralph Herbst serves as the Chief Strategy Officer at Asklepios BioPharmaceutical, Inc. (AskBio) since 2023. In this role, he plays a significant part in shaping the strategic direction of the company's gene therapy initiatives. His responsibilities include leading the development and implementation of strategies that align with AskBio's goals in the biotechnology sector.
Previous Experience in Pharmaceuticals
Herbst has extensive experience in the pharmaceutical industry, having held various leadership roles at Bayer Pharmaceuticals. He worked as Head of Strategy Implementation & Business Planning for the Cell & Gene Therapy Unit from 2021 to 2023. His previous positions at Bayer include Vice President roles in Business Planning and Strategy Development & Implementation, as well as Head of Cell & Gene Therapy Activator from 2018 to 2020.
Background in Engineering and Business
Ralph Herbst has a strong educational background in engineering and business. He studied Chemical Engineering at RWTH Aachen University, achieving a Diplom-Ingenieur / MS / Master of Science. He also completed an Executive MBA at Rotterdam School of Management, Erasmus University, and has participated in executive education programs at IMD and Saïd Business School, University of Oxford.
Leadership Roles at Covestro
Before his tenure at Bayer, Herbst held several key positions at Covestro. He served as Vice President & Head of Polyurethanes New Markets from 2009 to 2012 and as Executive Assistant to the Chairman & CEO from 2007 to 2009. His earlier role as Corporate Development Manager at Covestro from 2005 to 2007 further solidified his expertise in corporate strategy and development.
Achievements in Strategic Leadership
Ralph Herbst is known for his proven track record of transforming teams into high-performance business units. His extensive experience in leading strategy and business planning, particularly in cell and gene therapy, has enabled him to create and leverage networks that influence major business decisions. This expertise supports his strategic leadership in the biotechnology field.